Eulast.pngEuropean Long-acting Antipsychotics in Schizophrenia Trial

What is the study about?

EULAST is a large international trial comparing Paliperidone and Aripiprazole; two licensed and commonly prescribed antipsychotic medications. We will be investigating treatment efficacy, compliance rates and any potential side-effects, in both oral and depot administration.

Who can take part?

  • Be 18 years or older
  • Have a diagnosis of schizophrenia or other psychosis
  • The first psychotic episode occurred at least one year and no more than 7 years ago.

Individuals will be unable to take part if they:

  • Have been treated with one of the medications included in this study and either did not tolerate the medication or the medication did not have an effect on schizophrenia symptoms
  • Are currently treated with clozapine
  • Are a forensic patient

What is involved?

Participants are randomised to one of four different treatment groups:

  • Oral Paliperidone
  • Oral Aripiprazole
  • Depot Paliperidone
  • Depot Aripiprazole.

Participants in this study will receive this treatment for a period of 18 months. Participants are asked to visit the research clinic monthly for physical monitoring and mental health assessments.

How do I get involved?

If you are interested in taking part or would like some more information please contact Jessica True, Clinical Research Coordinator on 019327 222 47 or research@sabp.nhs.uk . Alternatively you can contact the Principle Investigator Dr Nilforooshan.